Search Results

You are looking at 11 - 20 of 41 items for :

  • "pamidronate" x
  • All content x
Clear All
Full access

Stephanie J. Lee

1982 ; 50 : 893 – 899 . 17 Berenson JR Lichtenstein A Porter L . Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group . N Engl J Med 1996 ; 334 : 488 – 493 . 18

Full access

Joanne Mortimer and Mary Mendelsohn

currently in the process of building electronic order sets for the electronic record. All orders for treating metastatic breast cancer include pamidronate, zoledronic acid, or denosumab. Adding orders for bone-directed therapies was recognized to be of

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group . J Clin Oncol. 1996 ; 14 : 2552 – 2559 . 212 Hortobagyi GN Theriault RL Lipton A . Long-term prevention of skeletal

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak

Premenopausal Women With Therapy-Induced Ovarian Suppression/Failure: Several studies reported that bisphosphonates, including zoledronic acid, pamidronate, clodronate, and risedronate, attenuate the bone loss associated with treatment-related ovarian failure

Full access

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak

also suggests that intravenous pamidronate or ibandronate, given every 3 months, has beneficial effects on bone density in women with postmenopausal osteoporosis. 33 , 34 Pamidronate has been studied specifically in patients with chemotherapy

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Cristina Gasparetto, Carol Ann Huff, Madan Jagasia, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Guido Tricot, Julie M. Vose, Donna Weber, Joachim Yahalom, and Furhan Yunus

complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma . Mayo Clin Proc 2005 ; 80 : 1568 – 1574 . 98 Berenson JR Lichtenstein A Porter L . Efficacy of pamidronate in reducing skeletal events in patients with

Full access

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, and Matthew R. Smith

receptor activity of primary human breast cancer and pattern of first metastasis . Breast Cancer Res Treat 1991 ; 18 : 27 – 32 . 11 Lipton A Theriault RL Hortobagyi GN . Pamidronate prevents skeletal complications and is effective palliative

Full access

Philip J. Saylor and Matthew R. Smith

similar claims-based analysis also found a significant association between GnRH agonist treatment and clinical fractures (relative risk [RR], 1.21; P < .001). 65 Bisphosphonates, including pamidronate, 66 , 67 zoledronic acid, 68 , 69

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr., Cristina Gasparetto, Carol Ann Huff, Adetola Kassim, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, and Furhan Yunus

.5 months compared with 44.5 months in the no-treatment group ( P = .9). Attal et al. 146 randomized 597 patients to either no maintenance, pamidronate alone, or pamidronate combined with thalidomide after tandem autologous SCT and found a highly

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

radiation therapy to boney sites. Early studies of pamidronate to prevent skeletal-related events confirmed its value in decreasing those events without direct impact on breast cancer or overall survival. 24 Subsequently, zoledronic acid and the monoclonal